Bukwang Pharmaceutical 過去の業績
過去 基準チェック /06
Bukwang Pharmaceutical's earnings have been declining at an average annual rate of -65.7%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been declining at an average rate of 3.5% per year.
主要情報
-65.7%
収益成長率
-65.8%
EPS成長率
| Pharmaceuticals 業界の成長 | 11.3% |
| 収益成長率 | -3.5% |
| 株主資本利益率 | -14.8% |
| ネット・マージン | -27.1% |
| 前回の決算情報 | 30 Jun 2024 |
最近の業績更新
Recent updates
Is Bukwang Pharmaceutical (KRX:003000) Weighed On By Its Debt Load?
May 22
Investors In Bukwang Pharmaceutical Co., Ltd. (KRX:003000) Should Consider This, First
Apr 03Did Bukwang Pharmaceutical's (KRX:003000) Share Price Deserve to Gain 71%?
Mar 08Is Bukwang Pharmaceutical (KRX:003000) A Risky Investment?
Feb 10How Much Of Bukwang Pharmaceutical Co., Ltd. (KRX:003000) Do Insiders Own?
Jan 14Does It Make Sense To Buy Bukwang Pharmaceutical Co., Ltd. (KRX:003000) For Its Yield?
Dec 19Did You Miss Bukwang Pharmaceutical's (KRX:003000) 90% Share Price Gain?
Nov 23収支内訳
Bukwang Pharmaceutical の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 30 Jun 24 | 116,583 | -31,551 | 42,683 | 33,877 |
| 31 Mar 24 | 123,087 | -28,336 | 41,243 | 34,601 |
| 31 Dec 23 | 125,928 | -31,330 | 46,377 | 34,551 |
| 30 Sep 23 | 162,391 | -19,773 | 55,088 | 27,225 |
| 30 Jun 23 | 191,782 | -4,355 | 55,177 | 25,270 |
| 31 Mar 23 | 191,230 | -5,259 | 55,479 | 25,328 |
| 31 Dec 22 | 190,909 | -2,475 | 52,698 | 24,274 |
| 30 Sep 22 | 183,371 | -1,326 | 48,029 | 23,960 |
| 30 Jun 22 | 181,552 | 25 | 46,775 | 21,422 |
| 31 Mar 22 | 182,548 | 179 | 45,961 | 20,619 |
| 31 Dec 21 | 182,491 | -917 | 45,170 | 22,465 |
| 30 Sep 21 | 178,012 | -4,380 | 46,032 | 23,753 |
| 30 Jun 21 | 170,537 | -11,194 | 45,543 | 22,783 |
| 31 Mar 21 | 168,711 | -9,475 | 45,802 | 20,664 |
| 31 Dec 20 | 169,660 | -7,203 | 46,636 | 18,032 |
| 30 Sep 20 | 171,579 | 140 | 48,751 | 16,618 |
| 30 Jun 20 | 170,969 | 2,817 | 52,693 | 17,873 |
| 31 Mar 20 | 170,116 | -11,057 | 54,233 | 17,070 |
| 31 Dec 19 | 168,194 | -7,412 | 54,193 | 17,312 |
| 30 Sep 19 | 158,981 | -17,457 | 51,101 | 19,919 |
| 30 Jun 19 | 195,507 | 129,926 | 52,554 | 21,421 |
| 31 Mar 19 | 194,863 | 144,874 | 52,677 | 23,822 |
| 31 Dec 18 | 194,224 | 145,670 | 52,650 | 24,640 |
| 30 Sep 18 | 191,641 | 150,191 | 51,782 | 24,972 |
| 30 Jun 18 | 153,731 | 9,501 | 46,077 | 23,748 |
| 31 Mar 18 | 152,120 | 8,878 | 45,444 | 26,767 |
| 31 Dec 17 | 150,743 | 11,091 | 45,567 | 25,067 |
| 30 Sep 17 | 144,306 | 8,093 | 47,383 | 22,041 |
| 30 Jun 17 | 140,675 | 4,067 | 49,271 | 22,520 |
| 31 Mar 17 | 139,578 | 6,664 | 46,944 | 17,485 |
| 31 Dec 16 | 138,618 | 15,807 | 46,408 | 18,677 |
| 30 Sep 16 | 143,162 | 22,757 | 35,339 | 28,532 |
| 30 Jun 16 | 144,390 | 33,640 | 32,542 | 27,118 |
| 31 Mar 16 | 141,975 | 33,891 | 44,176 | 16,954 |
| 31 Dec 15 | 142,132 | 25,139 | 42,607 | 14,879 |
| 30 Sep 15 | 139,543 | 25,356 | 53,486 | 3,251 |
| 30 Jun 15 | 139,197 | 21,736 | 52,536 | 1,928 |
| 31 Mar 15 | 138,956 | 22,783 | 38,489 | 12,874 |
| 31 Dec 14 | 141,687 | 23,616 | 40,497 | 10,229 |
| 30 Sep 14 | 139,681 | 22,981 | 38,557 | 8,943 |
| 30 Jun 14 | 136,857 | 23,001 | 37,311 | 7,979 |
| 31 Mar 14 | 133,484 | 22,331 | 36,151 | 7,242 |
| 31 Dec 13 | 130,795 | 19,532 | 38,160 | 7,242 |
質の高い収益: A003000 is currently unprofitable.
利益率の向上: A003000 is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: A003000 is unprofitable, and losses have increased over the past 5 years at a rate of 65.7% per year.
成長の加速: Unable to compare A003000's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: A003000 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.9%).
株主資本利益率
高いROE: A003000 has a negative Return on Equity (-14.82%), as it is currently unprofitable.